Partners L P/il Bvf's Net Worth

$3.89 Billion

Estimate Recalculated Feb 29, 2024 09:27PM EST

Who is Partners L P/il Bvf?

Partners L P/il Bvf has an estimated net worth of $3.89 Billion. This is based on reported shares across multiple companies, which include Allakos Inc., Rain Oncology Inc., ARENA PHARMACEUTICALS INC, IMMUNE DESIGN CORP., Cascadian Therapeutics, Inc., Capstone Therapeutics Corp., ChemoCentryx, Inc., DYNAVAX TECHNOLOGIES CORP, REPLIGEN CORP, KENT INTERNATIONAL HOLDINGS INC, NEUROCRINE BIOSCIENCES INC, XOMA Corp, LIGAND PHARMACEUTICALS INC, RIGEL PHARMACEUTICALS INC, Xenon Pharmaceuticals Inc., Cullinan Oncology, Inc., Merus N.V., Nivalis Therapeutics, Inc., Repare Therapeutics Inc., PIERIS PHARMACEUTICALS, INC., Verastem, Inc., Syndax Pharmaceuticals Inc, CTI BIOPHARMA CORP, IDEAYA Biosciences, Inc., CYTOKINETICS INC, Kymera Therapeutics, Inc., CURIS INC, Calithera Biosciences, Inc., CONCERT PHARMACEUTICALS, INC., PALATIN TECHNOLOGIES INC, MEDICINOVA INC, CATALYST BIOSCIENCES, INC., CytomX Therapeutics, Inc., MoonLake Immunotherapeutics, GLYCOMIMETICS INC, Principia Biopharma Inc., INFINITY PHARMACEUTICALS, INC., Eledon Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc., Regulus Therapeutics Inc., ADVANCED MAGNETICS INC, ESSA Pharma Inc., 4D Molecular Therapeutics, Inc., NPS PHARMACEUTICALS INC, ICAGEN INC, ADOLOR CORP, Third Harmonic Bio, Inc., ZONAGEN INC, COMBINATORX, INC, Regado Biosciences Inc, SUPERGEN INC, FIVE PRIME THERAPEUTICS, INC., Structure Therapeutics Inc., ARRAY BIOPHARMA INC, ARQULE INC, AEOLUS PHARMACEUTICALS, INC., INHIBITEX, INC., NEUROBIOLOGICAL TECHNOLOGIES INC /CA/, enGene Holdings Inc., Celera CORP, FACET BIOTECH CORP, PHARMACOPEIA INC, AVIGEN INC \DE, SGX PHARMACEUTICALS, INC., VIACELL INC, NEUROGEN CORP, POINT Biopharma Global Inc., GENAERA CORP, AEROGEN INC, CORVAS INTERNATIONAL INC, BIOCRYST PHARMACEUTICALS INC, and APPLIED MOLECULAR EVOLUTION INC.

SEC CIK

Partners L P/il Bvf's CIK is 0001055947

Past Insider Trading and Trends

2008 was Partners L P/il Bvf's most active year for acquiring shares with 351 total transactions. Partners L P/il Bvf's most active month to acquire stocks was the month of October. 2009 was Partners L P/il Bvf's most active year for disposing of shares, totalling 86 transactions. Partners L P/il Bvf's most active month to dispose stocks was the month of May. 2021 saw Partners L P/il Bvf paying a total of $132,144,944.64 for 12,405,370 shares, this is the most they've acquired in one year. In 2020 Partners L P/il Bvf cashed out on 18,981,731.772 shares for a total of $187,629,819.78, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Allakos Inc. (ALLK) Snapshot price: $1.28

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 3
0
0
No matching records found

Rain Oncology Inc. (RAIN) No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-8.58M
0
Jan 25 - Jan 26
Form 4
+47.80%
1.71M
$5.83
$9,971,387.14
5.29M
Nov 8
Form 4
+20.43%
557.73K
$12.00
$6,692,637.85
3.29M
Jan 6 - Jan 7
Form 4
+0.41%
11.03K
$13.94
$153,828.71
2.73M
Sep 21
Form 4
+16.86%
392.27K
$16.49
$6,468,515.81
2.72M
Sep 13
Form 4
+33.73%
587K
$15.47
$9,078,692.10
2.33M
Jul 1 - Jul 6
Form 4
+7.63%
123.35K
$15.94
$1,966,334.17
1.74M
May 21 - May 24
Form 4
+14.80%
208.47K
$16.59
$3,457,720.14
1.62M
May 18 - May 19
Form 4
+4.30%
58K
$14.26
$827,167.00
1.41M
May 13
Form 4/A
+522.18%
1.13M
$16.86
$19,103,379.78
1.35M
Apr 23 - Apr 26
Form 4
4.93M
$16.86
4.93M
Apr 23 - Apr 26
Form 3
0
0
No matching records found

ARENA PHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-12.32%
-828.09K
$5.10
-$4,219,175.99
5.89M
Jul 7 - Jul 8
Form 4
-3.35%
-95.00K
$5.42
-$514,900.00
2.74M
Jul 1
Form 4
-2.44%
-71.00K
$5.31
-$376,797.00
2.83M
Jun 29
Form 4
-0.92%
-54.00K
$5.36
-$287,009.90
5.82M
Jun 28
Form 4
-0.20%
-6.00K
$5.52
-$33,114.00
2.96M
Jun 18
Form 4
-3.39%
-104.00K
$5.40
-$561,600.00
2.97M
Jun 16
Form 4
-1.64%
-144.50K
$6.00
-$867,000.00
8.67M
Jan 20 - Jan 21
Form 4
-2.87%
-95.00K
$6.05
-$574,750.00
3.21M
Jan 14
Form 4
-0.72%
-24.00K
$6.30
-$151,200.00
3.31M
Jan 9
Form 4
-26.26%
-1.19M
$6.20
-$7,359,400.00
3.33M
Dec 31
Form 4
-39.17%
-2.91M
$7.69
-$22,385,590.00
4.52M
Oct 17
No matching records found

IMMUNE DESIGN CORP. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-15.77%
-902.00K
$1.83
-$1,653,907.20
4.82M
Dec 4
Form 3
0
0
No matching records found

Cascadian Therapeutics, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Jun 23
Form 3
0
0
Form 4
-41.40%
-4.00M
5.66M
Feb 5
Form 4
+4.08%
378.44K
$1.82
$688,678.86
9.66M
Dec 15 - Dec 17
Form 3
0
0
Form 4
-7.41%
-554.24K
$3.24
-$1,795,731.12
6.92M
Jul 16
Form 4
+1.76%
129K
$1.78
$229,620.00
7.48M
Nov 1
Form 4
+3.64%
258.36K
$1.65
$426,166.47
7.35M
Aug 8
Form 4
+5.01%
338.09K
$1.76
$589,602.29
7.09M
Jul 31 - Aug 1
Form 4
+1.09%
214.47K
$1.79
$387,225.99
19.95M
Jun 5 - Jun 7
Form 3
0
0
No matching records found